Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01494.x/abstract

Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical

practice and correlation with virological breakthroughs

W. Chotiyaputta, C. Hongthanakorn, K. Oberhelman, R. J. Fontana, T. Licari, A.

S. F. Lok

Article first published online: 14 JUL 2011

DOI: 10.1111/j.1365-2893.2011.01494.x

© 2011 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Early View (Online Version of Record published before inclusion in an issue)

Summary.  Medication adherence is important for the success of nucleos(t)ide

analogue (NUC) treatment for chronic hepatitis B. The aims of this study were to

determine adherence to NUCs and factors associated with NUC adherence and to

correlate NUC adherence with the occurrence of virological breakthroughs in

patients with chronic hepatitis B. Consecutive patients with chronic hepatitis B

receiving NUC were asked to complete a survey every 3 months. Adherence was also

assessed by healthcare providers in the clinic. Adherence rate was defined as

the per cent of days the patients took their hepatitis B virus medications

during the last 30 days. A total of 111 patients were studied. The mean age was

47.7 years, 73.9% were men, 57.7% were Asian, 42.3% had postgraduate education

and 80% had private insurance. Sixty-nine (74.1%) patients reported 100%

adherence in the survey, while 78 (83.9%) reported 100% adherence to their

healthcare providers. Patients with 100% adherence based on the survey were

older (P = 0.02), more likely to be men (P = 0.006), and had higher annual

household income (P = 0.04) than those with <100% adherence. In the 80 patients

who completed three surveys, viral breakthrough was observed in 1/46 (2.2%) with

100% adherence on all three surveys, 1/18 (5.6%) with <100% adherence on one

survey and 3/16 (18.8%) with <100% adherence on ≥2 surveys, (P = 0.06). In

conclusion, adherence to NUC therapy in our patients with chronic hepatitis B

was high but self-reporting of adherence to healthcare providers may be

inflated. Patients with chronic hepatitis B with better adherence to NUC therapy

had a trend towards a lower rate of viral breakthroughs.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01494.x/abstract

Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical

practice and correlation with virological breakthroughs

W. Chotiyaputta, C. Hongthanakorn, K. Oberhelman, R. J. Fontana, T. Licari, A.

S. F. Lok

Article first published online: 14 JUL 2011

DOI: 10.1111/j.1365-2893.2011.01494.x

© 2011 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Early View (Online Version of Record published before inclusion in an issue)

Summary.  Medication adherence is important for the success of nucleos(t)ide

analogue (NUC) treatment for chronic hepatitis B. The aims of this study were to

determine adherence to NUCs and factors associated with NUC adherence and to

correlate NUC adherence with the occurrence of virological breakthroughs in

patients with chronic hepatitis B. Consecutive patients with chronic hepatitis B

receiving NUC were asked to complete a survey every 3 months. Adherence was also

assessed by healthcare providers in the clinic. Adherence rate was defined as

the per cent of days the patients took their hepatitis B virus medications

during the last 30 days. A total of 111 patients were studied. The mean age was

47.7 years, 73.9% were men, 57.7% were Asian, 42.3% had postgraduate education

and 80% had private insurance. Sixty-nine (74.1%) patients reported 100%

adherence in the survey, while 78 (83.9%) reported 100% adherence to their

healthcare providers. Patients with 100% adherence based on the survey were

older (P = 0.02), more likely to be men (P = 0.006), and had higher annual

household income (P = 0.04) than those with <100% adherence. In the 80 patients

who completed three surveys, viral breakthrough was observed in 1/46 (2.2%) with

100% adherence on all three surveys, 1/18 (5.6%) with <100% adherence on one

survey and 3/16 (18.8%) with <100% adherence on ≥2 surveys, (P = 0.06). In

conclusion, adherence to NUC therapy in our patients with chronic hepatitis B

was high but self-reporting of adherence to healthcare providers may be

inflated. Patients with chronic hepatitis B with better adherence to NUC therapy

had a trend towards a lower rate of viral breakthroughs.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01494.x/abstract

Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical

practice and correlation with virological breakthroughs

W. Chotiyaputta, C. Hongthanakorn, K. Oberhelman, R. J. Fontana, T. Licari, A.

S. F. Lok

Article first published online: 14 JUL 2011

DOI: 10.1111/j.1365-2893.2011.01494.x

© 2011 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Early View (Online Version of Record published before inclusion in an issue)

Summary.  Medication adherence is important for the success of nucleos(t)ide

analogue (NUC) treatment for chronic hepatitis B. The aims of this study were to

determine adherence to NUCs and factors associated with NUC adherence and to

correlate NUC adherence with the occurrence of virological breakthroughs in

patients with chronic hepatitis B. Consecutive patients with chronic hepatitis B

receiving NUC were asked to complete a survey every 3 months. Adherence was also

assessed by healthcare providers in the clinic. Adherence rate was defined as

the per cent of days the patients took their hepatitis B virus medications

during the last 30 days. A total of 111 patients were studied. The mean age was

47.7 years, 73.9% were men, 57.7% were Asian, 42.3% had postgraduate education

and 80% had private insurance. Sixty-nine (74.1%) patients reported 100%

adherence in the survey, while 78 (83.9%) reported 100% adherence to their

healthcare providers. Patients with 100% adherence based on the survey were

older (P = 0.02), more likely to be men (P = 0.006), and had higher annual

household income (P = 0.04) than those with <100% adherence. In the 80 patients

who completed three surveys, viral breakthrough was observed in 1/46 (2.2%) with

100% adherence on all three surveys, 1/18 (5.6%) with <100% adherence on one

survey and 3/16 (18.8%) with <100% adherence on ≥2 surveys, (P = 0.06). In

conclusion, adherence to NUC therapy in our patients with chronic hepatitis B

was high but self-reporting of adherence to healthcare providers may be

inflated. Patients with chronic hepatitis B with better adherence to NUC therapy

had a trend towards a lower rate of viral breakthroughs.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01494.x/abstract

Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical

practice and correlation with virological breakthroughs

W. Chotiyaputta, C. Hongthanakorn, K. Oberhelman, R. J. Fontana, T. Licari, A.

S. F. Lok

Article first published online: 14 JUL 2011

DOI: 10.1111/j.1365-2893.2011.01494.x

© 2011 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Early View (Online Version of Record published before inclusion in an issue)

Summary.  Medication adherence is important for the success of nucleos(t)ide

analogue (NUC) treatment for chronic hepatitis B. The aims of this study were to

determine adherence to NUCs and factors associated with NUC adherence and to

correlate NUC adherence with the occurrence of virological breakthroughs in

patients with chronic hepatitis B. Consecutive patients with chronic hepatitis B

receiving NUC were asked to complete a survey every 3 months. Adherence was also

assessed by healthcare providers in the clinic. Adherence rate was defined as

the per cent of days the patients took their hepatitis B virus medications

during the last 30 days. A total of 111 patients were studied. The mean age was

47.7 years, 73.9% were men, 57.7% were Asian, 42.3% had postgraduate education

and 80% had private insurance. Sixty-nine (74.1%) patients reported 100%

adherence in the survey, while 78 (83.9%) reported 100% adherence to their

healthcare providers. Patients with 100% adherence based on the survey were

older (P = 0.02), more likely to be men (P = 0.006), and had higher annual

household income (P = 0.04) than those with <100% adherence. In the 80 patients

who completed three surveys, viral breakthrough was observed in 1/46 (2.2%) with

100% adherence on all three surveys, 1/18 (5.6%) with <100% adherence on one

survey and 3/16 (18.8%) with <100% adherence on ≥2 surveys, (P = 0.06). In

conclusion, adherence to NUC therapy in our patients with chronic hepatitis B

was high but self-reporting of adherence to healthcare providers may be

inflated. Patients with chronic hepatitis B with better adherence to NUC therapy

had a trend towards a lower rate of viral breakthroughs.